Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00126867 |
Recruitment Status
:
Recruiting
First Posted
: August 5, 2005
Last Update Posted
: January 16, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Colon Cancer |

Study Type : | Observational |
Estimated Enrollment : | 104 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment |
Study Start Date : | May 2005 |
Estimated Primary Completion Date : | March 2017 |
Estimated Study Completion Date : | March 2017 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- High risk Stage II or III colon cancer
- Eastern Cooperative Oncology Group performance status (ECOG P.S.) O or l
- No prior chemotherapy
- Complete tumor resection
- Candidate for and planned to receive standard capecitabine
- Adequate bone marrow reserve
Exclusion Criteria:
- Known DED deficiencies

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126867
Contact: Karen Mulder, MD | 780-432-8248 | karen.mulder@albertahealthservices.ca |
Canada, Alberta | |
Cross Cancer Institute | Recruiting |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Contact 780-432-8248 | |
Principal Investigator: Karen Mulder, MD |
Principal Investigator: | Karen Mulder, MD | AHS Cancer Control Alberta | |
Principal Investigator: | Michael Sawyer, MD | AHS Cancer Control Alberta |
Responsible Party: | AHS Cancer Control Alberta |
ClinicalTrials.gov Identifier: | NCT00126867 History of Changes |
Other Study ID Numbers: |
GI-05-0049 / 21882 |
First Posted: | August 5, 2005 Key Record Dates |
Last Update Posted: | January 16, 2017 |
Last Verified: | January 2017 |
Keywords provided by AHS Cancer Control Alberta:
thymidylate synthase polymers rapecitabine adjuvant colon cancer |
toxicity Stage II colon cancer Stage III colon cancer adenocarcinoma of the colon |
Additional relevant MeSH terms:
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Colonic Diseases |
Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Capecitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |